Proprietary Knowledgebase

Real-world longitudinal data on patients with cancer

Through the course of over 15 years of clinical testing of the responses of patient tumors to drugs, Helomics has amassed a huge proprietary knowledgebase of 150,000 patient cases. This data has been rigorously de-identified and aggregated to build a unique, proprietary model of tumor drug response that we call TumorSpace. The TumorSpace model and its data provide a priori knowledge for the machine learning approaches we employ as part of the PeDAL approach.

TumorSpace contains data from high quality, standardized drug response data from clinical testing and has a rich diversity of data from

  • 131 tumor types

  • 338 tumor sub-types

  • 643 anatomic sites

diversity of tumor cases in Helomics TumorSpace knowledgebase
divesity of tumor stages in Helomics TumorSpace

In addition TumorSpace contains data on

  • Clinical & demographic information

  • Biomarker and mutational profiles

  • Access to 10+ years of historical clinical outcome data

Opportunity for additional data acquisition and access to historical patient outcomes

In addition to the data within TumorSpace, Helomics has a very large number of archival FFPE blocks that under appropriate circumstances can be used for further data generation, such as Whole Genome , Whole Exome, and Whole Transcriptome sequencing. We have already demonstrated as part of our UPMC-Magee retrospective study that we can extract high-quality nucleic acid from our FFPE material and generate robust Whole Exome and Whole Transcriptome data. Furthermore, as a clinical laboratory whose oncologist ordered a sample for clinical testing, we are able to access historical patient outcome data, which offers a unique opportunity to sequence a tumor and very quickly have access to 10-plus years of survival data, without the lag of waiting for years to accumulate that information. As part of that same UPMC-Magee study, we have shown that we can indeed access this data to gain a clear picture of disease progression.

This provides a comprehensive tumor profile that includes

  • Tumor drug response to a panel of Standard-of-care drugs

  • Tumor pathology and clinical stage

  • H&E and IHC slides

  • Patient demographics

  • clinically actionable biomarkers

  • Whole exome

  • Whole transcriptome

  • Patient drug treatment regimen

  • Patient outcome ( Overall Survival (OFS) and Progression-Free Survival)

tumor drug response profiles in Helomics TumorSpace